The deficiency of adenosine deaminase type 2-results of therapeutic intervention
Amanda K. Ombrello(National Human Genome Research Institute), Daniel L. Kastner(National Institutes of Health), Beverly Barham(National Human Genome Research Institute), Ivona Aksentijevich(National Institutes of Health), Deborah L. Stone(National Institute of Arthritis and Musculoskeletal and Skin Diseases), Karyl S. Barron(National Institute of Allergy and Infectious Diseases), Anne Jones(National Human Genome Research Institute), Pallavi Kumar(Dr. Mohan's Diabetes Specialities Centre), Sherry L. Sheldon(National Institutes of Health Clinical Center), Qing Zhou(Hanzhong Central Hospital), Willy A. Flegel(National Institutes of Health Clinical Center), Patrycja Hoffmann(National Human Genome Research Institute), Michael S. Hershfield(Duke University)
Cited by 33
Related Papers
Activated STING in a Vascular and Pulmonary Syndrome
|New England Journal of Medicine|2014|1.4k
Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci
|Nature Genetics|2010|1.3k
<i>STAT4</i> and the Risk of Rheumatoid Arthritis and Systemic Lupus Erythematosus
|New England Journal of Medicine|2007|1.1k
Neonatal-Onset Multisystem Inflammatory Disease Responsive to Interleukin-1β Inhibition
|New England Journal of Medicine|2006|902
Early-Onset Stroke and Vasculopathy Associated with Mutations in ADA2
|New England Journal of Medicine|2014|889